🇺🇸 FDA

Intelligence · Clinical Pipeline

R&D Pipeline Programs

ClinicalTrials.gov programs linked to pharma sponsors — phase, modality, and trial IDs for BD and competitive intelligence.

Programs indexed
20,548
Companies
1,769
Drugs tracked
4,797

Quick answer

NovaPharmaNews tracks 20,548 pharmaceutical R&D pipeline programs sourced from ClinicalTrials.gov, linked to sponsor companies. Each profile includes development phase, modality, trial status, NCT identifiers, and indication text — searchable for business development and competitive intelligence.

382 results for “Ology” Clear

  1. Ziftomenib, Ziftomenib

    Kura Oncology

    Relapsed and/or refractory Acute Myeloid Leukemia

    phase 2 small molecule active

    1 trial

  2. capecitabine

    Cardiff Oncology

    Pancreatic Cancer

    phase 2 small molecule completed

    1 trial

  3. carboplatin

    Cardiff Oncology

    Bladder Cancer

    phase 2 small molecule completed

    1 trial

  4. cisplatin

    Cardiff Oncology

    Bladder Cancer

    phase 2 small molecule completed

    2 trials

  5. encaleret

    BridgeBio Oncology Therapeutics

    Post-Surgical Hypoparathyroidism

    phase 2 small molecule completed

    1 trial

  6. etrasimod

    MAIA Biotechnology

    Pouchitis

    phase 2 small molecule active

    1 trial

  7. evorpacept

    ALX ONCOLOGY HOLDINGS INC

    Head and Neck Cancer

    phase 2 small molecule active

    2 trials

  8. evorpacept, KEYTRUDA 25 mg/mL concentrate for solution for infusion

    Wuhan Createrna Science and Technology Co., Ltd

    metastatic or unresectable, recurrent HNSCC

    phase 2 small molecule active

    1 trial

  9. neratinib

    PUMA BIOTECHNOLOGY, INC.

    HER2-mutant Non-Small Cell Lung Cancer

    phase 2 small molecule completed

    1 trial

  10. neratinib

    PUMA BIOTECHNOLOGY, INC.

    Breast Neoplasms

    phase 2 small molecule completed

    3 trials

  11. oncolytic adenovirus expressing GMCSF

    CG Oncology

    Bladder Cancer

    phase 2 mab terminated

    1 trial

  12. sirolimus

    Cardiff Oncology

    Tuberous Sclerosis

    phase 2 small molecule active

    1 trial

  13. volrustomig, Monalizumab

    Pari Pharma GmbH

    cancerology

    phase 2 small molecule active

    1 trial

  14. A Phase 1 First-in-Human Study of the Safety and Effects of VIR-5818 Alone or with Pembrolizumab in Participants with Advanced or Metastatic HER2-Expressing Cancers

    Vir Biotechnology

    Participants with Locally Advanced or Metastatic HER2-Expressing Cancers

    phase 1 other active

    1 trial

  15. A Phase 1 study to evaluate IK-930 in subjects with advanced solid tumors

    Wuhan Createrna Science and Technology Co., Ltd

    Advanced Solid Tumors

    phase 1 other active

    1 trial

  16. A Phase 1, Double-blind, Randomized, Placebo-controlled, First-in-Human Study of Orally Administered DF-006 to Evaluate the Safety, Tolerability, and Pharmacokinetics After a Single Dose and Multiple Doses of Orally Administered DF-006 in Healthy Subjects (Part 1 and Part 2) and in Chronic Hepatitis B Patients (Part 3). Protocol Number Df-006-1001

    Wuhan Createrna Science and Technology Co., Ltd

    Chronic Hepatitis B

    phase 1 other active

    1 trial

  17. A Study to Investigate the Safety and Tolerability of Ziftomenib Combinations in Patients with Relapsed/Refractory Acute Myeloid Leukemia

    Kura Oncology

    Relapsed and/or refractory Acute Myeloid Leukemia

    phase 1 other active

    1 trial

  18. A Study to evaluate the effect of a high-fat meal on the Pharmacokinetics of the Selective MET kinase Inhibitor DO-2 in subjects in good health

    Wuhan Createrna Science and Technology Co., Ltd

    Healthy volunteer

    phase 1 other active

    1 trial

  19. AG10 oral tablet

    BridgeBio Oncology Therapeutics

    Amyloid Cardiomyopathy, Transthyretin-Related

    phase 1 small molecule completed

    1 trial

  20. ALX2004

    ALX ONCOLOGY HOLDINGS INC

    NSCLC (Advanced Non-small Cell Lung Cancer)

    phase 1 small molecule active

    1 trial

  21. APX005M treatment for recurrent or refractory primary malignant CNS tumor patients

    Pyxis Oncology

    Glioblastoma Multiforme

    phase 1 mab active

    1 trial

  22. BBO-10203

    BridgeBio Oncology Therapeutics

    Solid Tumor, Adult

    phase 1 small molecule active

    1 trial

  23. BBO-11818

    BridgeBio Oncology Therapeutics

    Non-Small Cell Lung Cancer

    phase 1 small molecule active

    1 trial

  24. BBO-8520

    BridgeBio Oncology Therapeutics

    Non-small Cell Lung Cancer

    phase 1 small molecule active

    1 trial

Frequently asked questions

What is the NovaPharmaNews pipeline directory?

It is a searchable index of 20,548 clinical development programs grouped by sponsor company, with phase (Phase 1–3), modality, trial status, and linked NCT IDs from ClinicalTrials.gov.

Where does pipeline data come from?

Program records are derived from ClinicalTrials.gov and linked to NovaPharmaNews company profiles. Trial status and phase reflect registry data at last sync — verify on ClinicalTrials.gov before investment or partnering decisions. See our data sources page for attribution.

How do I find pipeline programs by company or phase?

Use the search box to match program name, indication, company name, or slug. Results are ordered with late-stage (Phase 3) programs first. Open any row to view the full program profile under its sponsor company.

Data attribution and licensing: Data sources